FDA Grants Priority Review for Belite Bio’s Stargardt Disease Treatment
Event summary
- FDA accepted Belite Bio’s NDA for tinlarebant, granting Priority Review designation.
- Target action date set for February 12, 2027.
- Tinlarebant demonstrated a 35.7% reduction in atrophic retinal lesion growth rate in Phase 3 DRAGON trial.
- If approved, tinlarebant would be the first-ever FDA-approved treatment for Stargardt Disease Type 1.
The big picture
Belite Bio’s NDA acceptance for tinlarebant marks a significant milestone in the treatment of Stargardt Disease Type 1, a rare inherited retinal condition with no current approved therapies. The Priority Review designation underscores the unmet medical need and the potential impact of tinlarebant on patients facing progressive vision loss. This development comes amid growing interest in treatments for degenerative retinal diseases, positioning Belite Bio as a key player in this niche therapeutic area.
What we're watching
- Regulatory Approval
- Whether the FDA will approve tinlarebant by the PDUFA date of February 12, 2027.
- Commercial Readiness
- The pace at which Belite Bio can prepare for commercial launch if approved.
- Market Impact
- How the approval of tinlarebant will affect the treatment landscape for Stargardt Disease Type 1.
Related topics